Navigation Links
New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities

CHAPEL HILL, N.C., July 11, 2014 /PRNewswire/ -- Patient engagement has become a critical component of pharmaceutical marketing and, consequently, organizations are turning to an assortment of marketing activities designed specifically for patients.

As part of this evolving approach to patient engagement, marketers have learned it's important to educate, communicate and engage patients throughout their experiences with a disease - from disease awareness to patient empowerment. By mapping the patient journey and employing a consumer marketing program that follows this path, marketing groups can more effectively engage with patients.

To better understand this strategic shift in patient marketing, Best Practices, LLC conducted a study to investigate how companies are adopting a "Patient Journey" framework to acquire, convert, support, and retain patients for their medical products. The resulting report, "Patient-Focused Marketing: Engagement Milestones along the Patient Journey," produced reliable industry metrics on current spending levels and investment allocation patterns for marketing to and communicating with patients.

The study employed a six-step framework to trace the patient journey and to identify what patient-focused initiatives, marketing activities, and investment levels are most effective for engaging patients during each phase of their journey.  On average, companies spend more than half their patient engagement funds during the first three stages of the patient journey - awareness, diagnosis and treatment consideration, according to the study. With the exception of the U.S. company segment, study participants focus their spend on the treatment consideration stage; diabetes companies place the highest emphasis here.

Marketing leaders can use this study to evaluate how their patient engagement programs compare with industry averages and trends.

Key topics addressed in this report include:

  • Investment in Patient-Focused Activities & Programs
  • Future Investment Levels in the Patient Journey
  • Investment within Patient Marketing, Foundation & Leadership Categories
  • Deployment of Patient-Focused Activities & Programs
  • Activities Timing Across the Patient Journey
  • Best Practices Shared by Benchmark Participants
  • Effective Patient Loyalty Programs
  • Pitfalls for Patient Marketers to Avoid

The research is based on a benchmarking survey instrument that engaged 22 leaders at 19 companies. Qualitative data came from in-depth interviews with seven participants. To learn more about this report, download a complimentary report excerpt at

For more information on other recent primary research studies, contact us at 919.403.0251. For related research, visit our Best Practices, LLC Web site at


Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

SOURCE Best Practices, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Veran Medical Publishes Lung Cancer Patient Management Study
2. Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
3. Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
4. Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
5. First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
6. Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
7. Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
8. EndoChoice Announces Investigator-Initiated Study Program for Fuse Endoscopy System
9. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
10. New England Journal of Medicine Study Finds Upper-Airway Electronic Stimulation Effective for Obstructive Sleep Apnea
11. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 - Will ... Medical Education (CME) --> - Will ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) ... products and services, will feature latest diagnostic imaging textbooks and decision ...
(Date:11/25/2015)... 25, 2015 Research and Markets ( ... Market - Global Forecast to 2020" report to ... accounting for 37.21% of the total market share in ... region is projected to growth at the highest ... attributed primarily to the fast growing water, industrial gas ...
(Date:11/25/2015)... --> --> ... für das Patent über eine neue Hepatitis-B-Behandlung, welches sie ... an Enyo Pharma vergeben haben. Im Rahmen ... und von Edelris gemeinsam mit seinen Partnern Inserm und ... HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... Tuberous Sclerosis Complex (TSC), as well as raising public awareness of the disorder ... need it—presented a third donation of $35,000 to bolster progress at the Tuberous ...
(Date:11/25/2015)... ... ... Since its launch in 2012, the Regenestem brand ( ... to patients with chronic degenerative medical conditions. Now, the U.S. Patent and Trademark ... Organizations are required to hold a registered trademark in order to make licensing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to ... of the Create Real Impact awards. California Casualty is proud to support ... tide of distracted and reckless driving, the number one killer of young drivers. ...
Breaking Medicine News(10 mins):